Symbols / CUE Stock $23.01 -9.16% Cue Biopharma, Inc.

Healthcare • Biotechnology • United States • NCM
CUE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Shao-Lee Lin M.D., Ph.D.
Exch · Country NCM · United States
Market Cap 93.09M
Enterprise Value 79.09M
Income -19.52M
Sales 32.73M
FCF (ttm) -13.61M
Book/sh 8.21
Cash/sh 4.31
Employees 29
Insider 10d —
IPO Jan 02, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -47.94
PEG —
P/S 2.84
P/B 2.80
P/C —
EV/EBITDA -4.36
EV/Sales 2.42
Quick Ratio 3.34
Current Ratio 3.57
Debt/Eq 15.92
LT Debt/Eq —
EPS (ttm) -4.53
EPS next Y -0.48
EPS Growth —
Revenue Growth 12.51%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-16
Earnings (prior) 2026-03-16
ROA -46.08%
ROE -138.52%
ROIC —
Gross Margin -6.45%
Oper. Margin -94.32%
Profit Margin -59.65%
Shs Outstand 4.05M
Shs Float 3.61M
Insider Own 13.63%
Instit Own 5.29%
Short Float 8.91%
Short Ratio 0.32
Short Interest 288.89K
52W High 41.42
vs 52W High -44.45%
52W Low 4.98
vs 52W Low 362.05%
Beta —
Impl. Vol. 0.00%
Rel Volume 0.24
Avg Volume 735.70K
Volume 180.04K
Target (mean) $115.00
Tgt Median $115.00
Tgt Low $115.00
Tgt High $115.00
# Analysts 1
Recom Strong_buy
Prev Close $25.33
Price $23.01
Change -9.16%
About

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$115.00
Mean price target
2. Current target
$23.01
Latest analyst target
3. DCF / Fair value
$-60.53
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$23.01
Low
$115.00
High
$115.00
Mean
$115.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-25 init LUCID CAPITAL MARKETS — → Buy $4
2025-04-02 reit Citizens Capital Markets Market Outperform → Market Outperform $2
2024-08-20 main Stifel Buy → Buy $4
2024-07-26 main JMP Securities Market Outperform → Market Outperform $2
2024-07-26 main Piper Sandler Overweight → Overweight $3
2024-04-09 main Stifel Buy → Buy $8
2024-04-09 main Oppenheimer Outperform → Outperform $10
2024-04-03 reit Piper Sandler Overweight → Overweight $8
2024-03-13 init Jefferies — → Buy $6
2023-11-06 main Piper Sandler Overweight → Overweight $8
2023-06-15 reit Stifel Buy → Buy $8
2023-05-15 reit JMP Securities Outperform → Outperform $15
2023-03-22 main Stifel — → Buy $8
2023-03-22 reit Oppenheimer — → Outperform $10
2022-11-21 init Piper Sandler — → Overweight $7
2022-08-24 main Oppenheimer — → Outperform $10
2022-03-21 main Oppenheimer — → Outperform $26
2022-03-18 main Craig-Hallum — → Buy $26
2020-11-24 init Berenberg — → Buy $30
2020-05-20 main Stifel — → Buy $30
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-30 SARRAF PASHA Director — 323,857 $0.30 $99,747
2024-12-16 PASSERI DANIEL R Chief Executive Officer — 30,000 $1.03 $30,900
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
27.47
+195.75%
9.29
+69.16%
5.49
+340.96%
1.25
Operating Revenue
27.47
+195.75%
9.29
+69.16%
5.49
+340.96%
1.25
Operating Expense
53.99
+6.11%
50.88
-11.49%
57.48
+5.00%
54.75
Research And Development
37.74
+3.99%
36.30
-11.05%
40.80
+5.76%
38.58
Selling General And Administration
16.24
+11.37%
14.59
-12.56%
16.68
+3.16%
16.17
General And Administrative Expense
16.24
+11.37%
14.59
-12.56%
16.68
+3.16%
16.17
Salaries And Wages
—
—
8.93
-4.86%
9.38
Other Gand A
16.24
+11.37%
14.59
-12.56%
16.68
+183.24%
5.89
Total Expenses
53.99
+6.11%
50.88
-11.49%
57.48
+5.00%
54.75
Operating Income
-26.52
+36.24%
-41.59
+20.00%
-51.99
+2.82%
-53.50
Total Operating Income As Reported
-26.55
+36.02%
-41.50
+20.42%
-52.15
+2.02%
-53.23
EBITDA
-22.27
+40.67%
-37.53
+18.51%
-46.05
+8.79%
-50.49
Normalized EBITDA
-22.23
+40.90%
-37.62
+18.03%
-45.90
+9.60%
-50.77
Reconciled Depreciation
3.48
+48.09%
2.35
-31.61%
3.44
+90.25%
1.81
EBIT
-25.75
+35.44%
-39.88
+19.42%
-49.49
+5.37%
-52.30
Total Unusual Items
-0.03
-133.33%
0.09
+159.24%
-0.16
-156.68%
0.28
Total Unusual Items Excluding Goodwill
-0.03
-133.33%
0.09
+159.24%
-0.16
-156.68%
0.28
Special Income Charges
-0.03
-133.33%
0.09
+159.24%
-0.16
-156.68%
0.28
Impairment Of Capital Assets
—
—
—
-0.28
Net Income
-26.60
+34.60%
-40.67
+19.83%
-50.73
+4.30%
-53.01
Pretax Income
-26.10
+35.83%
-40.67
+19.83%
-50.73
+4.30%
-53.01
Net Non Operating Interest Income Expense
0.45
-45.52%
0.83
-41.67%
1.42
+558.60%
0.21
Interest Expense Non Operating
0.36
-55.15%
0.80
-36.06%
1.25
+74.61%
0.71
Net Interest Income
0.45
-45.52%
0.83
-41.67%
1.42
+558.60%
0.21
Interest Expense
0.36
-55.15%
0.80
-36.06%
1.25
+74.61%
0.71
Interest Income Non Operating
0.81
-50.25%
1.62
-39.05%
2.66
+186.75%
0.93
Interest Income
0.81
-50.25%
1.62
-39.05%
2.66
+186.75%
0.93
Other Income Expense
-0.03
-133.33%
0.09
+159.24%
-0.16
-156.68%
0.28
Tax Provision
0.50
0.00
—
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
-0.01
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-26.60
+34.60%
-40.67
+19.83%
-50.73
+4.30%
-53.01
Net Income From Continuing Operation Net Minority Interest
-26.60
+34.60%
-40.67
+19.83%
-50.73
+4.30%
-53.01
Net Income From Continuing And Discontinued Operation
-26.60
+34.60%
-40.67
+19.83%
-50.73
+4.30%
-53.01
Net Income Continuous Operations
-26.60
+34.60%
-40.67
+19.83%
-50.73
+4.30%
-53.01
Normalized Income
-26.58
+34.81%
-40.77
+19.39%
-50.58
+5.09%
-53.29
Net Income Common Stockholders
-26.60
+34.60%
-40.67
+19.83%
-50.73
+4.30%
-53.01
Diluted EPS
-0.28
+98.70%
-21.60
+35.14%
-33.30
+25.50%
-44.70
Basic EPS
-0.28
+98.70%
-21.60
+35.14%
-33.30
+25.50%
-44.70
Basic Average Shares
94.73
+4945.34%
1.88
+23.11%
1.53
+28.35%
1.19
Diluted Average Shares
94.73
+4945.34%
1.88
+23.11%
1.53
+28.35%
1.19
Diluted NI Availto Com Stockholders
-26.60
+34.60%
-40.67
+19.83%
-50.73
+4.30%
-53.01
Gain On Sale Of PPE
-0.03
-133.33%
0.09
+159.24%
-0.16
-156.68%
0.28
Rent And Landing Fees
—
—
0.72
-20.36%
0.90
Rent Expense Supplemental
—
—
0.72
-20.36%
0.90
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
42.21
+31.13%
32.19
-47.68%
61.53
-32.59%
91.28
Current Assets
36.98
+47.12%
25.14
-51.14%
51.45
-33.34%
77.19
Cash Cash Equivalents And Short Term Investments
27.14
+20.82%
22.46
-53.71%
48.51
-36.41%
76.29
Cash And Cash Equivalents
27.14
+20.82%
22.46
-53.71%
48.51
-6.01%
51.61
Other Short Term Investments
—
—
0.00
-100.00%
24.68
Receivables
7.45
+687.83%
0.94
-44.35%
1.70
+2878.95%
0.06
Accounts Receivable
5.55
+486.88%
0.94
-44.35%
1.70
+2878.95%
0.06
Taxes Receivable
1.90
0.00
—
—
Prepaid Assets
1.09
+17.65%
0.93
+223.69%
0.29
—
Other Current Assets
1.31
+62.61%
0.81
-15.71%
0.95
+13.56%
0.84
Total Non Current Assets
5.23
-25.86%
7.05
-30.00%
10.08
-28.52%
14.10
Net PPE
4.32
-10.87%
4.84
-31.99%
7.12
-33.49%
10.70
Gross PPE
7.98
-6.37%
8.52
-20.62%
10.73
-28.17%
14.94
Accumulated Depreciation
-3.66
+0.46%
-3.68
-1.77%
-3.62
+14.76%
-4.24
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
—
6.32
-31.29%
9.20
Machinery Furniture Equipment
0.28
+10.89%
0.25
+10.71%
0.22
-40.58%
0.38
Construction In Progress
—
—
—
—
Other Properties
7.58
-6.99%
8.15
-21.53%
10.39
+98.09%
5.25
Leases
0.12
+0.00%
0.12
+0.00%
0.12
+0.00%
0.12
Non Current Prepaid Assets
0.67
-65.93%
1.96
-27.32%
2.69
-13.67%
3.12
Other Non Current Assets
0.25
-3.50%
0.26
-4.10%
0.27
-3.60%
0.28
Total Liabilities Net Minority Interest
15.78
+7.41%
14.69
-39.90%
24.45
-4.52%
25.60
Current Liabilities
13.49
-1.42%
13.69
-19.86%
17.08
+47.91%
11.55
Payables And Accrued Expenses
5.46
+39.45%
3.92
-27.68%
5.42
+35.07%
4.01
Payables
4.64
+64.26%
2.82
-19.37%
3.50
+28.19%
2.73
Accounts Payable
3.95
+39.85%
2.82
-19.37%
3.50
+28.19%
2.73
Other Payable
0.69
—
—
—
Current Accrued Expenses
0.83
-24.45%
1.10
-42.86%
1.92
+49.73%
1.28
Pensionand Other Post Retirement Benefit Plans Current
0.78
-56.79%
1.81
-18.34%
2.22
-2.38%
2.27
Current Debt And Capital Lease Obligation
1.91
-75.73%
7.87
+7.39%
7.33
+39.29%
5.26
Current Debt
—
4.33
+9.34%
3.96
+101.88%
1.96
Other Current Borrowings
—
4.33
+9.34%
3.96
+101.88%
1.96
Current Capital Lease Obligation
1.91
-46.02%
3.54
+5.11%
3.37
+2.06%
3.30
Current Deferred Liabilities
5.33
+6176.47%
0.09
-95.98%
2.11
0.00
Current Deferred Revenue
5.33
+6176.47%
0.09
-95.98%
2.11
0.00
Other Current Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
2.29
+127.92%
1.00
-86.38%
7.36
-47.60%
14.05
Long Term Debt And Capital Lease Obligation
2.29
+127.92%
1.00
-86.38%
7.36
-47.60%
14.05
Long Term Debt
—
—
4.20
-47.70%
8.04
Long Term Capital Lease Obligation
2.29
+127.92%
1.00
-68.28%
3.16
-47.46%
6.02
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Revenue
—
—
—
—
Stockholders Equity
26.43
+51.05%
17.50
-52.81%
37.09
-43.54%
65.68
Common Stock Equity
26.43
+51.05%
17.50
-52.81%
37.09
-43.54%
65.68
Capital Stock
0.10
+56.45%
0.06
+31.91%
0.05
+9.30%
0.04
Common Stock
0.10
+56.45%
0.06
+31.91%
0.05
+9.30%
0.04
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
3.22
+56.30%
2.06
+30.93%
1.57
+9.69%
1.43
Ordinary Shares Number
3.22
+56.30%
2.06
+30.93%
1.57
+9.69%
1.43
Additional Paid In Capital
394.80
+9.88%
359.30
+6.23%
338.23
+6.97%
316.19
Retained Earnings
-368.47
-7.78%
-341.86
-13.50%
-301.19
-20.26%
-250.46
Gains Losses Not Affecting Retained Earnings
—
—
0.00
+100.00%
-0.10
Other Equity Adjustments
—
—
—
-0.10
Total Equity Gross Minority Interest
26.43
+51.05%
17.50
-52.81%
37.09
-43.54%
65.68
Total Capitalization
26.43
+51.05%
17.50
-57.62%
41.29
-43.99%
73.72
Working Capital
23.49
+105.16%
11.45
-66.69%
34.37
-47.63%
65.64
Invested Capital
26.43
+21.07%
21.83
-51.75%
45.25
-40.21%
75.68
Total Debt
4.20
-52.72%
8.88
-39.60%
14.70
-23.92%
19.32
Capital Lease Obligations
4.20
-7.62%
4.54
-30.43%
6.53
-29.92%
9.32
Net Tangible Assets
26.43
+51.05%
17.50
-52.81%
37.09
-43.54%
65.68
Tangible Book Value
26.43
+51.05%
17.50
-52.81%
37.09
-43.54%
65.68
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-21.69
+40.30%
-36.33
+9.09%
-39.96
+4.41%
-41.81
Cash Flow From Continuing Operating Activities
-21.69
+40.30%
-36.33
+9.09%
-39.96
+4.41%
-41.81
Net Income From Continuing Operations
-26.60
+34.60%
-40.67
+19.83%
-50.73
+4.30%
-53.01
Depreciation Amortization Depletion
3.48
+48.09%
2.35
-31.61%
3.44
+90.25%
1.81
Depreciation
3.48
+48.09%
2.35
-31.61%
3.44
+90.25%
1.81
Depreciation And Amortization
3.48
+48.09%
2.35
-31.61%
3.44
+90.25%
1.81
Other Non Cash Items
0.17
+0.00%
0.17
+0.00%
0.17
+221.90%
-0.14
Stock Based Compensation
4.74
-30.70%
6.85
-16.31%
8.18
-13.86%
9.50
Operating Gains Losses
0.03
+133.33%
-0.09
-159.24%
0.16
+3825.00%
0.00
Gain Loss On Sale Of PPE
0.03
+133.33%
-0.09
-159.24%
0.16
+3825.00%
0.00
Change In Working Capital
-3.29
+33.10%
-4.92
-427.30%
-0.93
-362.36%
0.36
Change In Receivables
-6.50
-963.21%
0.75
+145.89%
-1.64
-153.19%
3.08
Changes In Account Receivables
-4.60
-711.02%
0.75
+145.89%
-1.64
-153.19%
3.08
Change In Prepaid Assets
0.01
-95.88%
0.24
+872.00%
0.03
+106.93%
-0.36
Change In Payables And Accrued Expense
0.52
+127.11%
-1.91
-240.43%
1.36
+237.45%
-0.99
Change In Accrued Expense
-1.30
-5.53%
-1.23
-309.01%
0.59
+154.90%
-1.07
Change In Payable
1.81
+367.55%
-0.68
-188.05%
0.77
+827.71%
0.08
Change In Account Payable
1.12
+265.93%
-0.68
-188.05%
0.77
+827.71%
0.08
Change In Other Working Capital
5.25
+359.00%
-2.03
-195.98%
2.11
+427.44%
-0.65
Change In Other Current Assets
—
—
—
0.00
Change In Other Current Liabilities
-2.57
-29.44%
-1.99
+28.73%
-2.79
-279.32%
-0.73
Investing Cash Flow
0.07
+134.38%
0.03
-99.87%
25.00
+201.59%
-24.61
Cash Flow From Continuing Investing Activities
0.07
+134.38%
0.03
-99.87%
25.00
+201.59%
-24.61
Net PPE Purchase And Sale
-0.14
-528.13%
0.03
+1500.00%
0.00
+101.21%
-0.17
Purchase Of PPE
-0.18
-168.18%
-0.07
0.00
+100.00%
-0.17
Sale Of PPE
0.04
-59.18%
0.10
+4800.00%
0.00
-66.67%
0.01
Capital Expenditure
-0.18
-168.18%
-0.07
—
-0.17
Net Investment Purchase And Sale
0.21
0.00
-100.00%
25.00
+202.27%
-24.45
Purchase Of Investment
-16.29
0.00
0.00
+100.00%
-29.45
Sale Of Investment
16.50
0.00
-100.00%
25.00
+400.00%
5.00
Financing Cash Flow
26.29
+156.67%
10.24
-13.63%
11.86
-77.90%
53.66
Cash Flow From Continuing Financing Activities
26.29
+156.67%
10.24
-13.63%
11.86
-77.90%
53.66
Net Issuance Payments Of Debt
-4.50
-12.53%
-4.00
-99.95%
-2.00
-120.00%
10.00
Issuance Of Debt
—
—
0.00
-100.00%
10.00
Repayment Of Debt
-4.50
-12.53%
-4.00
-99.95%
-2.00
0.00
Long Term Debt Issuance
—
—
0.00
-100.00%
10.00
Long Term Debt Payments
-4.50
-12.53%
-4.00
-99.95%
-2.00
0.00
Net Long Term Debt Issuance
-4.50
-12.53%
-4.00
-99.95%
-2.00
-120.00%
10.00
Net Common Stock Issuance
30.79
+116.47%
14.22
+6.25%
13.39
-65.94%
39.30
Proceeds From Stock Option Exercised
0.00
-100.00%
0.02
-96.19%
0.47
-89.94%
4.70
Net Other Financing Charges
—
—
—
-0.34
Changes In Cash
4.68
+117.96%
-26.05
-740.72%
-3.10
+75.71%
-12.76
Beginning Cash Position
22.61
-53.54%
48.66
-5.99%
51.76
-19.77%
64.52
End Cash Position
27.29
+20.69%
22.61
-53.54%
48.66
-5.99%
51.76
Free Cash Flow
-21.86
+39.93%
-36.40
+8.92%
-39.96
+4.80%
-41.98
Interest Paid Supplemental Data
0.21
-68.01%
0.67
-33.30%
1.00
+75.96%
0.57
Amortization Of Securities
-0.21
0.00
+100.00%
-0.23
+27.10%
-0.32
Common Stock Issuance
30.79
+116.47%
14.22
+6.25%
13.39
-65.94%
39.30
Issuance Of Capital Stock
30.79
+116.47%
14.22
+6.25%
13.39
-65.94%
39.30
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category